← Back to Search

H2 Receptor Antagonist

Famotidine + Antacids for Indigestion

Phase 4
Recruiting
Research Sponsored by Stony Brook University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject Age ≥ 18 years of age
Patient diagnosed with dyspepsia
Must not have
Kidney Failure
Inability to tolerate oral medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 hour
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial aims to compare the effectiveness of intravenous famotidine (an H2 receptor antagonist) and Maalox/Mylanta (an oral antacid) in treating dyspepsia in

Who is the study for?
This trial is for adults over 18 with dyspepsia, experiencing upper abdominal pain of at least a moderate level. It's not suitable for those with severe kidney issues, pregnant or nursing women, people who can't take oral meds, have bowel obstruction, recently took proton pump inhibitors, or are allergic to the study medications.
What is being tested?
The study compares intravenous Famotidine and oral Maalox/ Mylanta in treating indigestion in emergency department patients. The goal is to see which medication reduces pain more effectively within an hour based on patient-reported pain levels.
What are the potential side effects?
Possible side effects include headaches, constipation or diarrhea from Famotidine; and chalky taste, stomach cramps or nausea from Maalox/ Mylanta. Reactions vary by individual.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with indigestion.
Select...
I have severe upper abdominal pain.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have kidney failure.
Select...
I cannot take medications by mouth.
Select...
I have a blockage in my intestines.
Select...
I take a proton pump inhibitor less than 2 hours before my study treatment.
Select...
My pain level is usually below 3 on a scale of 0-10.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 hour for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Verbal Numerical Pain Score
Secondary study objectives
Need for Rescue Medications
Satisfaction with Assigned Medication

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Active Control
Group I: Intravenous FamotidineActive Control1 Intervention
Patients in this group will receive 20 mg of intravenous famotidine.
Group II: Oral MaaloxActive Control1 Intervention
Patients in the group will receive 30 ml of oral Maalox/ Mylanta.

Find a Location

Who is running the clinical trial?

Stony Brook UniversityLead Sponsor
222 Previous Clinical Trials
41,951 Total Patients Enrolled
~40 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top